Printer Friendly

Nymox Files PMA Amendment with FDA for Alzheimer Urine Test.

MAYWOOD, N.J. -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that it has filed an amendment to its Premarket Approval application (PMA) for the Company's urine NTP test kit with the FDA. The PMA amendment was filed in response to the Company's discussions and meetings with the FDA. The Company believes that the remaining requirements from the Company's meetings and discussions with the FDA will be completed and filed in the next 30 to 60 days.

The urine NTP test kit is a kit version of the Company's AlzheimAlert(TM) test and is designed for sale to clinical laboratories and hospitals for on-site testing of patient urine samples using the kit.

The NTP test is a non-invasive urine test intended to help physicians in the diagnosis of Alzheimer's disease. The test measures the level of a brain protein called neural thread protein (NTP) known to be elevated in the urine of patients with Alzheimer's disease. There is an extensive scientific and medical literature on NTP and its relationship to Alzheimer's disease and on its clinical accuracy and utility as an aid to the diagnosis of Alzheimer's disease. Publications include, for example, Journal of Alzheimer's Disease (2004; 6(3): 231-42) and (2001; 3: 345-353); Cellular and Molecular Life Sciences (2003; 60: 2679-91) and (2001; 58: 844-849); Alzheimer's Reports (2002; 1: 1-6); Neurology & Clinical Neurophysiology (2002; 1: 2-7); Frontiers in Bioscience (2002; 7:d989-96); Journal of Neuropathology and Experimental Neurology (2001; 60: 195-207) and (1996; 55: 1038-1050); Neurology (2000; 55: 1068) and (2000; 54: 1498-1504); Alzheimer's Reports (2001; 4: 61-65), (2000; 3: 177-184) and (1999; 2: 327-332); Journal of Clinical Laboratory Analysis (1998; 12: 285-288) and (1998; 12: 223-226); Journal of Contemporary Neurology (1998; 4A: 2-6); and Journal of Clinical Investigation (1997; 100: 3093-3104).

More information about Nymox is available at, email:, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:Nov 4, 2004
Previous Article:Ericsson chosen by DiGi for nationwide EDGE expansion in Malaysia.
Next Article:TIM Hellas 9-Months 2004 Summary Financial and Customer Results.

Related Articles
Nymox AD Protein Marker Linked to New Cell Death Mechanism in Alzheimer's Disease.
Nymox Pharmaceutical Rated ''Bullish'' by Standard & Poor's Stock Reports.
Nymox Files Data with FDA for Alzheimer Urine Test.
Insulin Abnormalities Linked to Alzheimer's Disease by Researchers; Nymox AD Protein Marker -NTP- Is Linked to Impaired Insulin Function and...
Nymox Reports 2004 Financial Results.
Nymox Makes Major Progress in Global Marketing of Company's Proprietary Alzheimer Test.
Nymox Alzheimer Product Featured in Cover Story of Clinical Laboratory News.
Nymox PMA Slated for FDA Advisory Panel Meeting.
FDA Advisory Panel Meeting for Nymox PMA Application Expected in July 2005.
Nymox Moves Forward With Global Marketing Agreements For Company's Proprietary AlzheimAlert-TM Test.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters